5 results
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
PrimaryTo evaluate the long-term safety and tolerability of baricitinib in patients with SLE.
To evaluate the effect of baricitinib 4-mg QD and background standard-of-care therapy compared with placebo and background standard-of-care therapy on SLE disease activity.
The objective of this study is to evaluate [11C]MeDAS PET as a quantitative method for assessment of changes in myelin density over time and thus the efficacy of [11C]MeDAS PET to image myelin degradation and repair.
The primary objective is to test the hypothesis that baricitinib high dose level in combination with topical corticosteroids (TCS) or baricitinib medium dose level in combination with TCS is superior to placebo in combination with TCS in the…